| Pack Size | Single Vial, 10-Pack |
|---|
5-Amino-1MQ is a small-molecule NNMT enzyme inhibitor. 5-Amino-1MQ — formally 5-amino-1-methylquinolinium iodide — is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). The compound is a quinolinium scaffold with a methyl substituent at position 1 and an amino substituent at position 5, supplied as the iodide salt for stability. The compound has been studied across multiple research streams covering its mechanism, biological-activity profile, and translational-research framings. Every Ronin batch is independently verified by Janoshik Analytical using HPLC for purity and mass spectrometry for identity, with the minimum acceptance threshold set at 99 percent purity by HPLC. Supplied as a lyophilized powder in a sealed glass vial, 50 mg per vial. For laboratory research use only — not for human or veterinary use.
Description
5-Amino-1MQ — formally 5-amino-1-methylquinolinium iodide — is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). The compound is a quinolinium scaffold with a methyl substituent at position 1 and an amino substituent at position 5, supplied as the iodide salt for stability.
NNMT (nicotinamide N-methyltransferase) catalyses the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. NNMT inhibition by 5-Amino-1MQ preserves the cellular nicotinamide pool — important for NAD+ biosynthesis — and conserves the methyl-donor pool by reducing SAM consumption. The compound has been investigated in adipocyte-research and metabolic-disease research contexts where elevated NNMT activity has been linked to insulin resistance and adipose-tissue dysfunction.
The compound is supplied as a lyophilized white-to-off-white powder in a sealed amber-glass vial under inert gas. Each vial contains 50 mg of compound. Reconstitution with bacteriostatic water is required before the compound can be drawn into an insulin syringe. Researchers planning bench preparations should review the Reconstitution accordion below for mechanics.
5-Amino-1MQ has been characterised across an expanding research literature spanning NNMT enzyme inhibition mechanism, adipocyte and obesity research, methyl-donor pool conservation, NAD+ pathway research, cancer-research framings (NNMT overexpression in tumours).
The 2017 Neelakantan paper in Biochemistry characterised a fluorescent assay for direct real-time monitoring of NNMT enzymatic activity, providing the analytical foundation for inhibitor screening including 5-Amino-1MQ (PMID 28121423). The 2021 Akar paper in Journal of Obstetrics and Gynaecology documented anti-proliferative activity of small-molecule NNMT inhibitors in HeLa cell systems (PMID 33645410). The 2022 Dimet-Wiley paper in Scientific Reports characterised NNMT inhibition combined with reduced-calorie diet in diet-induced-obesity mouse model systems (PMID 35013352). The 2024 Yang paper in Journal for ImmunoTherapy of Cancer documented NNMT in cancer-associated fibroblasts driving tumour progression (PMID 39067875).
Across the literature the compound appears under several alternate identifiers: 5-Amino-1MQ; 5-amino-1-methylquinolinium iodide; quinolinium NNMT inhibitor. The CAS registry number 63-39-8 anchors the canonical chemical identifier.
No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared 5-Amino-1MQ for therapeutic use in humans or animals. The compound has not progressed through a drug-approval pathway in any major jurisdiction. Ronin Peptides ships the compound exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.
Mechanism in research literature
NNMT (nicotinamide N-methyltransferase) catalyses the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. NNMT inhibition by 5-Amino-1MQ preserves the cellular nicotinamide pool — important for NAD+ biosynthesis — and conserves the methyl-donor pool by reducing SAM consumption. The compound has been investigated in adipocyte-research and metabolic-disease research contexts where elevated NNMT activity has been linked to insulin resistance and adipose-tissue dysfunction.
The 2017 Neelakantan paper in Biochemistry characterised a fluorescent assay for direct real-time monitoring of NNMT enzymatic activity, providing the analytical foundation for inhibitor screening including 5-Amino-1MQ (PMID 28121423). The 2021 Akar paper in Journal of Obstetrics and Gynaecology documented anti-proliferative activity of small-molecule NNMT inhibitors in HeLa cell systems (PMID 33645410). The 2022 Dimet-Wiley paper in Scientific Reports characterised NNMT inhibition combined with reduced-calorie diet in diet-induced-obesity mouse model systems (PMID 35013352). The 2024 Yang paper in Journal for ImmunoTherapy of Cancer documented NNMT in cancer-associated fibroblasts driving tumour progression (PMID 39067875).
Multiple groups have studied, examined, and characterised the compound across in vitro, ex vivo, and animal-model preparations. The mechanism research has produced both basic-science findings on the molecular targets and translational-research observations in disease-model systems. The 2026 broader peptide-therapy reviews (PMID 41966639) place this compound class in the wider research-context of unapproved compounds under active investigation.
Researchers planning new work should consult the most current literature on this compound class to position findings against the broader mechanism-niche framework. Independent groups have observed consistent patterns across the published research record, providing cross-laboratory replication for the core mechanism findings documented in the foundational papers cited above.
Recent broader peptide-therapy reviews compile contemporary research framings around the broader compound class within which this molecule sits. The 2026 Sports Medicine and JAAOS Global Research and Reviews papers (PMID 41966639, PMID 41490200) place multiple compounds — including this one — into the wider research context of unapproved compounds under active investigation, with attention to both the mechanism findings and the regulatory framing that researchers consulting these reviews should weigh equally.
Studied properties
The published research record on 5-Amino-1MQ spans multiple decades. Most of this corpus consists of cell-culture and rodent-model investigations. The foundational mechanism work has been complemented by translational-research investigations in disease-model systems and by recent contemporary reviews compiling the broader research framework.
The 2017 Neelakantan paper in Biochemistry characterised a fluorescent assay for direct real-time monitoring of NNMT enzymatic activity, providing the analytical foundation for inhibitor screening including 5-Amino-1MQ (PMID 28121423). The 2021 Akar paper in Journal of Obstetrics and Gynaecology documented anti-proliferative activity of small-molecule NNMT inhibitors in HeLa cell systems (PMID 33645410). The 2022 Dimet-Wiley paper in Scientific Reports characterised NNMT inhibition combined with reduced-calorie diet in diet-induced-obesity mouse model systems (PMID 35013352). The 2024 Yang paper in Journal for ImmunoTherapy of Cancer documented NNMT in cancer-associated fibroblasts driving tumour progression (PMID 39067875).
Independent replication of the foundational findings across multiple research groups provides cross-laboratory credibility for the core mechanism observations. The pattern of consistent findings across in vitro, ex vivo, and animal-model contexts has shaped the contemporary research-context framing for the compound.
Translation to human clinical application has been narrower than the breadth of the preclinical literature would suggest. The contemporary research framing places the compound in a research-supply position rather than a clinical-development position. Researchers consulting recent reviews (PMID 41966639) should attend to the regulatory framing as much as the mechanism framing.
Recent literature has expanded the application bracket through novel research streams. Investigators have studied the compound in combination with other research molecules, in biomaterial-integrated delivery formats, and in cell-type-specific contexts that broaden the mechanism understanding documented in foundational papers. The expansion-era literature continues to add depth to the compound's research profile.
Cross-stream research framings have continued to expand the application bracket through novel investigation contexts. Investigators have studied the compound across cell-type-specific exposures, biomaterial-integrated delivery formats, and combination protocols with adjacent research compounds. The cumulative literature represents an active expansion-era research stream where new findings appear regularly across the international peer-reviewed publication record. Researchers consulting recent reviews should attend to both the foundational mechanism papers cited in the references and the contemporary expansion-era publications that document ongoing methodological refinements and emerging research applications.
The published research record is broadly accessible through major scientific databases including PubMed, Web of Science, and Scopus, with PMID identifiers cited inline throughout this page providing direct access to the foundational literature. Researchers planning new experimental work should consult the most recent literature beyond the citations provided here, since the research record continues to expand and the contemporary research-context framing benefits from inclusion of the most current findings. Independent groups have characterised the compound across overlapping research model systems, providing cross-laboratory replication for the core observations documented in the foundational papers.
Compound specifications
| Specification | Value |
|---|---|
| Common name | 5-Amino-1MQ |
| Alternate names | 5-Amino-1MQ; 5-amino-1-methylquinolinium iodide; quinolinium NNMT inhibitor |
| Class | Small-molecule NNMT inhibitor (not a peptide) |
| Molecular formula | C10H11IN2 |
| Molecular weight | 286.11 g/mol (iodide salt form) |
| CAS number | 63-39-8 |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 10 mg, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC (verified per batch by Janoshik Analytical) |
Storage and handling
Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.
Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands.
After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window for a reconstituted preparation is four to six weeks at fridge temperature. The 0.9% benzyl alcohol in bacteriostatic water suppresses microbial growth but does not arrest hydrolysis, oxidation, or aggregation processes accumulating in any aqueous compound solution over time.
When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on molecular structure, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature.
The reconstituted product should be visually clear and colourless. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.
Compare with similar compounds
| Compound | Primary research area | Documented mechanism (preclinical) | Format at Ronin |
|---|---|---|---|
| 5-Amino-1MQ | Metabolic; NNMT inhibition | NNMT enzyme inhibitor; methyl-donor pool conservation | 10 mg vial |
| NAD+ | Aging; mitochondrial function | Coenzyme; sirtuin/PARP/CD38 substrate | 500 mg vial |
| MOTS-c | Metabolic regulation | AMPK pathway activation | 10 mg vial |
| AOD-9604 | Lipolytic research | Modified hGH 176-191 fragment | 5 mg vial |
5-Amino-1MQ sits within Ronin's metabolic compound category, alongside related compounds in the catalog. Researchers exploring related research areas often examine 5-Amino-1MQ in combination with other compounds in the same mechanism niche, or comparatively against compounds that engage adjacent pathways.
Reconstitution and laboratory handling
A 50 mg vial reconstituted with 2 mL of bacteriostatic water yields 25 mg/mL. With 1 mL: 10 mg/mL. With 5 mL: 2 mg/mL. The compound is a small molecule rather than a peptide; reconstitution dynamics are simpler than peptide reconstitution but the same bacteriostatic-water diluent applies.
Reconstitution procedure:
- Bring both vials — compound and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures compound at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.
For dose-volume calculations on insulin syringes, use the Ronin reconstitution calculator.
In published preclinical research, 5-Amino-1MQ has been administered across multiple model systems with varying routes documented in the literature (PMID 28121423, PMID 33645410, PMID 35013352, PMID 39067875). These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.
Frequently asked questions
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule NNMT enzyme inhibitor. 5-Amino-1MQ — formally 5-amino-1-methylquinolinium iodide — is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT). The compound is a quinolinium scaffold with a methyl substituent at position 1 and an amino substituent at position 5, supplied as the iodide salt for stability. The compound has been characterised across multiple research streams covering NNMT enzyme inhibition mechanism, adipocyte and obesity research, methyl-donor pool conservation, NAD+ pathway research, cancer-research framings (NNMT overexpression in tumours). Ronin supplies the compound as a lyophilized vial reconstituted with bacteriostatic water at the bench. Sale is limited to laboratory research applications; human and veterinary use are excluded.
What is the regulatory status?
No regulatory body — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has approved 5-Amino-1MQ as a drug for human or veterinary use. The compound has not progressed through a drug-approval pathway in any major jurisdiction.
The compound is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. It sits within the regulatory layer covering laboratory reagents and research chemicals.
Ronin Peptides supplies the compound as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is 5-Amino-1MQ verified?
Each batch passes through Janoshik Analytical — an independent peptide-analytics lab — for HPLC purity quantification and MS identity confirmation, with the minimum acceptance threshold set at 99 percent purity by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com. To pull the COA covering the batch on your order, email support@roninpeptides.ca from the address used at checkout, with your order number; the typical reply turnaround is well under 24 hours.
How is 5-Amino-1MQ reconstituted?
A 50 mg vial reconstituted with 2 mL of bacteriostatic water yields 25 mg/mL. With 1 mL: 10 mg/mL. With 5 mL: 2 mg/mL. The compound is a small molecule rather than a peptide; reconstitution dynamics are simpler than peptide reconstitution but the same bacteriostatic-water diluent applies. Inject the water against the inside wall of the vial — never directly onto the lyophilized powder, which causes foaming and surface denaturation. Swirl gently or invert slowly until fully dissolved (typically 30–60 seconds). Refrigerate at 2–8 °C immediately. Use the Ronin reconstitution calculator for non-standard volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch. COAs are not published publicly to protect supply-chain privacy and prevent competitor scraping.
References
- Neelakantan H et al. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of NNMT Activity. Biochemistry. 2017. PMID: 28121423 | doi:10.1021/acs.biochem.6b01215
- Akar S et al. Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity. J Obstet Gynaecol. 2021. PMID: 33645410 | doi:10.1080/01443615.2020.1854696
- Dimet-Wiley A et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome. Sci Rep. 2022. PMID: 35013352 | doi:10.1038/s41598-021-03670-5
- Yang M et al. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression. J Immunother Cancer. 2024. PMID: 39067875 | doi:10.1136/jitc-2024-009281
- Cantó C et al. NAD(+) precursor nicotinamide riboside enhances oxidative metabolism. Cell Metab. 2012. PMID: 22682224 | doi:10.1016/j.cmet.2012.04.022
- Yoshino J et al. NAD(+) Intermediates: Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018. PMID: 29249689 | doi:10.1016/j.cmet.2017.11.002
- Tang QQ et al. Adipogenesis: from stem cell to adipocyte. Annu Rev Biochem. 2012. PMID: 22463691 | doi:10.1146/annurev-biochem-052110-115718
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies. Sports Med. 2026. PMID: 41966639 | doi:10.1007/s40279-026-02437-0
